Want to see IN:BLUEJET full AI Analyst Report?
Top Page
Blue Jet Healthcare Limited
(BLUEJET)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹548.00
▼(-16.14% Downside)
Action:Downgraded
Date:10/12/26
The score is mainly supported by strong profitability and a very low-debt balance sheet, which add resilience. The biggest drags are the FY2026 revenue decline and inconsistent cash conversion, alongside weak technical momentum (below key moving averages) and a relatively high P/E with a low dividend yield.
Positive Factors
Strong and sustained profitability
Consistently high gross and net margins indicate that Blue Jet has maintained meaningful economics across multiple years. This profitability can support reinvestment, absorb some cost pressure, and provide a stronger foundation for growth than a low-margin API business.
Negative Factors
Material FY2026 revenue contraction
The sharp FY2026 revenue decline interrupts the company’s earlier expansion and reduces visibility into demand and operating scale. If weaker sales persist, fixed-cost absorption, customer ordering patterns, and the ability to sustain historical profitability could all come under pressure.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong and sustained profitability
Consistently high gross and net margins indicate that Blue Jet has maintained meaningful economics across multiple years. This profitability can support reinvestment, absorb some cost pressure, and provide a stronger foundation for growth than a low-margin API business.
Read all positive factors
Blue Jet Healthcare Limited (BLUEJET) vs. iShares MSCI India ETF (INDA)
Market Cap
₹95.37B
Dividend Yield0.24%
Average Volume (3M)28.97K
Price to Earnings (P/E)37.2
Beta (1Y)1.48
Revenue Growth-27.51%
EPS Growth-34.49%
CountryIN
Employees581
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)13.55
Shares Outstanding189,275,700
10 Day Avg. Volume13,702
30 Day Avg. Volume28,971
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)4.17
Price to Sales (P/S)5.99
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)17.04
Revenue Forecast (FY)₹11.79B
Blue Jet Healthcare Limited Business Overview & Revenue Model
Company Description
Blue Jet Healthcare Ltd. is a company that focuses on the manufacturing and supply of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), which are critical components for the pharmaceutical and healthcare sectors. Its produ...
How the Company Makes Money
Blue Jet Healthcare Limited primarily makes money by selling pharmaceutical raw materials—mainly APIs and intermediates—to other pharmaceutical companies that use these inputs to manufacture finished medicines. Revenue is generated from (1) produc...
Blue Jet Healthcare Limited Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
91
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.86B | 9.47B | 10.30B | 7.10B | 7.18B | 6.77B |
| Gross Profit | 3.94B | 4.14B | 5.61B | 3.89B | 2.70B | 2.97B |
| EBITDA | 2.95B | 2.94B | 4.24B | 2.48B | 2.43B | 2.69B |
| Net Income | 2.35B | 2.48B | 3.05B | 1.64B | 1.60B | 1.82B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 16.41B | 14.18B | 10.59B | 8.62B | 7.13B |
| Cash, Cash Equivalents and Short-Term Investments | 3.23B | 3.76B | 3.06B | 3.09B | 2.55B | 1.81B |
| Total Debt | 0.00 | 421.84M | 199.86M | 16.13M | 68.31M | 228.39M |
| Total Liabilities | -13.60B | 2.81B | 2.84B | 2.14B | 1.81B | 1.92B |
| Stockholders Equity | 13.60B | 13.60B | 11.33B | 8.45B | 6.81B | 5.22B |
Cash Flow | ||||||
| Free Cash Flow | 817.22M | 0.00 | -341.15M | 669.59M | 822.79M | 1.23B |
| Operating Cash Flow | 2.07B | 3.38B | 457.65M | 2.41B | 1.42B | 1.46B |
| Investing Cash Flow | -1.65B | -2.84B | -351.83M | -2.64B | -1.47B | -760.26M |
| Financing Cash Flow | -85.36M | -259.95M | -185.57M | -19.86M | -42.33M | -561.45M |
Blue Jet Healthcare Limited Technical Analysis
Negative
653.45
Price Trends
552.37
Negative
555.69
Negative
487.66
Positive
Market Momentum
-16.28
Negative
41.92
Neutral
59.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLUEJET, the sentiment is Negative. The current price of 653.45 is above the 20-day moving average (MA) of 514.68, above the 50-day MA of 552.37, and above the 200-day MA of 487.66, indicating a neutral trend. The MACD of -16.28 indicates Negative momentum. The RSI at 41.92 is Neutral, neither overbought nor oversold. The STOCH value of 59.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BLUEJET.
Blue Jet Healthcare Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹128.67B | 45.65 | ― | 0.61% | 4.02% | -12.81% | |
63 Neutral | ₹95.37B | 37.16 | ― | 0.24% | -27.51% | -34.49% | |
56 Neutral | ₹23.37B | 34.35 | ― | 0.11% | -20.86% | -34.51% | |
56 Neutral | ₹160.78B | 86.09 | ― | 0.31% | -5.99% | -60.30% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹180.00B | -10,464.00 | ― | ― | 10.66% | -104.59% | |
49 Neutral | ₹573.10B | 103.50 | ― | 0.14% | 9.83% | 5.07% |
* General Sector Average
IN:BLUEJET
Blue Jet Healthcare Limited
503.85
-142.45
-22.04%
IN:BIOCON
Biocon Limited
352.00
-24.55
-6.52%
IN:CONCORDBIO
Concord Biotech Ltd.
1,229.90
-214.25
-14.84%
IN:DCAL
Dishman Carbogen Amcis Ltd.
149.05
-144.25
-49.18%
IN:SYNGENE
Syngene International Ltd.
398.30
-250.41
-38.60%
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,569.65
-280.90
-15.18%
Blue Jet Healthcare Limited Corporate Events
Blue Jet Healthcare Publishes Q1 FY2026 Unaudited Standalone Results
Aug 4, 2026
Blue Jet Healthcare Limited has announced the publication of its unaudited standalone financial results for the quarter ended June 30, 2026. The company disclosed that extracts of these quarterly figures have been carried in leading newspapers Fin...
Blue Jet Healthcare releases Q1 FY27 investor presentation
Aug 3, 2026
Blue Jet Healthcare Limited has released an analysts and investors presentation detailing its financial results for the first quarter ended June 30, 2026, corresponding to Q1 FY27. The disclosure, made under Indian listing regulations, signals the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.